[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565523":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":34,"responsibleParty":91,"collaborators":94,"id":104,"slug":18,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":105,"sex":111,"minAge":112,"maxAge":18,"enrollmentInfo":113,"targetDuration":18,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Participants receive access to the Digizorg Melanoma app, on top of care as usual.",[13],"Device: Digizorg Melanoma app",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Participants have access to care as usual, but have no access to the Digizorg Melanoma app and its functionalities.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","Digizorg Melanoma app","The Digizorg Melanoma app is a digital survivorship care plan, in which ellaborated information regarding diagnosis, treatment and follow-up and supportive care, adjusted to one's personal preferences and disease characteristics, is offered in the form of a mobile application.",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Marjolein Lugtenberg, PhD","CONTACT","+31614448940","m.lugtenberg@erasmusmc.nl",{"name":32,"role":28,"phone":18,"phoneExt":18,"email":33},"June Kievits, MD","j.kievits@erasmusmc.nl",[35,55,68,80],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Albert Schweitzer hospital","RECRUITING","Dordrecht","South Holland","3318 AT","Netherlands","NL",{"type":44,"coordinates":45},"Point",[46,47],4.67361,51.81,{"lat":47,"lon":46},[50,53],{"name":51,"role":28,"phone":18,"phoneExt":18,"email":52},"Peter Plaisier, PhD","p.w.plaisier@asz.nl",{"name":51,"role":54,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"facility":56,"status":37,"city":57,"state":39,"zip":58,"country":41,"countryCode":42,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Erasmus MC","Rotterdam","3015GD",{"type":44,"coordinates":60},[61,62],4.47917,51.9225,{"lat":62,"lon":61},[65,67],{"name":27,"role":28,"phone":66,"phoneExt":18,"email":30},"+316 144488940",{"name":27,"role":54,"phone":18,"phoneExt":18,"email":18},{"facility":69,"status":70,"city":57,"state":39,"zip":71,"country":41,"countryCode":42,"cosmosGeoPoint":72,"geoPoint":74,"contacts":75},"Franciscus Gasthuis & Vlietland hospital","NOT_YET_RECRUITING","3045 PM",{"type":44,"coordinates":73},[61,62],{"lat":62,"lon":61},[76,79],{"name":77,"role":28,"phone":18,"phoneExt":18,"email":78},"Frederique Beverdam, PhD","f.beverdam@franciscus.nl",{"name":77,"role":54,"phone":18,"phoneExt":18,"email":18},{"facility":81,"status":37,"city":57,"state":39,"zip":82,"country":41,"countryCode":42,"cosmosGeoPoint":83,"geoPoint":85,"contacts":86},"Maasstad hospital","3079 DZ",{"type":44,"coordinates":84},[61,62],{"lat":62,"lon":61},[87,90],{"name":88,"role":28,"phone":18,"phoneExt":18,"email":89},"Kai Munte, MD","munteK@maasstadziekenhuis.nl",{"name":88,"role":54,"phone":18,"phoneExt":18,"email":18},{"type":54,"investigatorFullName":92,"investigatorTitle":93,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Marjolein Lugtenberg","Doctor",[95,98,100,102],{"name":96,"class":97},"BeterKeten","UNKNOWN",{"name":99,"class":6},"Albert Schweitzer Hospital",{"name":101,"class":6},"Maasstad Hospital",{"name":103,"class":6},"Franciscus Gasthuis","100565523",false,"NCT06643286","Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma","Personalised Survivorship Care for Patients With Melanoma: A Multicenter Randomised Controlled Trial of the Survivorship Care Plan App","Melanoma SCP","Inclusion Criteria:\n\n* 18 years or older\n* Patients who have received a primary diagnosis of cutaneous melanoma stage I to II in the past 0-4 months\n\nExclusion Criteria:\n\n* Patients with irresectable stage III melanoma, patients receiving neo-adjuvant treatment and patients with stage IV melanoma.\n* Patients who do not have (sufficient) command of the Dutch language.","ALL","18 Years",{"count":114,"type":115},180,"ESTIMATED","INTERVENTIONAL",[118],"NA","A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app. A total of hundred-eighty melanoma patients (stage I and II) will be randomised to receive either the SCP Melanoma app or usual care. The app provides survivors with personalized healthcare information on diagnosis, treatment and follow-up and supportive care, tailored to their melanoma stage and phase and information needs.Through questionnaires, medical file records, patient-reported outcomes and use of medical care will be evaluated. In addition, log-data, questionnaires and interviews will be used to evaluate the process of the uptake and implementation of the digital SCP.",[121,122,123,124],"Melanoma (Skin)","Melanoma, Stage II, Stage I","Melanoma Stage","Survivorship",[126,127,128],"Survivorship care","Application","RCT","2025-06-06",{"date":131,"type":132},"2025-06-11","ACTUAL",{"date":134,"type":132},"2025-04-01",{"date":136,"type":115},"2026-12-01",{"name":5,"class":6},4]